Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Portable Sensor Detects Gluten In Foods For Those With Celiac Disease



Nima is a small but highly-sensitive device capable of detecting trace amounts of gluten in food. Image courtesy of Nima.

Tweetables from this article:

Tweet: 3 million people affected by #celiac disease in the US http://ctt.ec/43IMN+3 million people affected by celiac disease in the US.

Tweet: FDA: Maximum concentration of gluten for “gluten-free” foods is 20 ppm http://ctt.ec/4rdbB+85,000 to 110,000 US patients experience recurring Clostridium difficile infections.

Share this!

July 8, 2016 | by Sarah Massey, M.Sc.

Gluten intolerance and celiac disease can be difficult to manage, especially when consuming food prepared outside the home. Since even small amounts of the protein can trigger serious reactions, how can someone be sure a menu item really is “gluten-free”?

Enter the Nima – a small but highly-sensitive device capable of detecting trace amounts of gluten in food. Nima was developed by MIT graduates Shireen Yates and Scott Sundvor, who are the CEO and Chief Product Officer for the company, respectively.

Celiac disease is an autoimmune disorder in which a patient suffers intestinal damage when gluten protein is eaten. The disease affects about 3 million people in the US, according to the National Institutes of Health (NIH). Millions more are thought to suffer from other types of gluten intolerance, according to the National Foundation for Celiac Awareness.

The three-inch-tall Nima device utilizes disposable capsules, into which individuals can insert a small amount of food or liquid. Once inserted into the Nima, the food-filled capsule comes in contact with a proprietary solution containing gluten-detecting antibodies.

In just over two minutes, the digital display indicates whether the food tested does or does not contain gluten. The results are automatically sent to a Nima app which allows users to enter additional information – such as where they ate, what dish was tested and whether it contained gluten – that is publicly available to all Nima users.

“Right now, we don’t know what’s in our food, whether it is allergens, pesticides, or other harmful chemicals,” Sundvor told MIT News. “There’s not a good way to get that data. We want to give people the ability to understand their food better and how it affects their health.”

As the maximum concentration of gluten allowable by the US Food and Drug Administration (FDA) for “gluten-free” foods is 20 parts per million (ppm), Nima can detect the protein at this concentration. Nima owes its high level of sensitivity to the immunoassay developed primarily by the company’s lead scientist and MIT alumnus, Dr. Jingqing Zhang.

At the core of Nima’s immunoassay technology are custom antibodies capable of detecting miniscule amounts of gluten in a sample. Once the antibodies bind to a gluten molecule, it triggers a colorimetric reaction which can then be detected by an optical reader.

Nima’s simplified display allows diners to make quick choices about whether or not a dish is safe to eat. A “gluten found” message is displayed if any gluten is detected by the device, otherwise the sensor will display a smiley face indicating that the food contains less than 20 ppm of the protein.

Even foods designed to be gluten-free can contain trace amounts of gluten, particularly if they come in contact with surfaces contaminated with the allergen. “It’s the equivalent to finding a breadcrumb in an entire plate of food,” said Sundvor.

Keywords: Food, Autoimmune Disorder, Intolerance


Share this with your colleagues!

New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News

Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News

Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


Strategies for Deploying Innovative Solutions for Perimeter Security

Natural History vs. Registry Studies in Rare Disease

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act

Copyright © 2016-2017 Honeycomb Worldwide Inc.